Presents an Educational and Informative Audio Webinar
Mechanistic
Understanding of
Disease Biomarkers
through Metabolomics
Broadcast Date: Wednesday, May 27, 2009
Time: 10:00 am PT, 1:00 pm EDT, 7:00 pm CDT, and 19:00 CET
Of all the omics disciplines, metabolomics is perhaps the most underutilized but potentially the most powerful for understanding disease mechanisms. It provides a complete biochemical profile of a cell or tissue under a specific set of conditions. Metabolomics can help identify disease mechanisms, markers for diagnostic tests, and targets for drug discovery.
Quantifying the metabolome is more tractable than the other omics, since the number of endogenous metabolites is lower than the number of genes, transcripts, or proteins. The chemical diversity and concentration ranges of biochemicals and metabolites involved, however, provide formidable challenges when searching for metabolomic biomarkers.
The Mechanistic Understanding of Disease Biomarkers through Metabolomics webinar will explore the basic of metabolomics and how the technology has been applied to the discovery of markers and pathways associated with drug action and disease. It will also cover two case studies related to prostate cancer and sepsis.
Who should attend?
- Systems biologists
- Any researcher who needs an understanding of the relationship between the metabolome and disease states
- Biomarker specialists involved in R&D for drugs, biopharma, or basic research
- Omics researchers working on drug discovery, metabolism, or development
- Cell biologists in the pharmaceutical or biopharmaceutical industries
Speakers
Arun Sreekumar, Ph.D., Assistant Professor, Medical College of Georgia, will discuss recently published (Nature, February 12, 2009) work on unbiased metabolomic profiles that distinguish benign prostate disease, localized prostate cancer, and metastatic malignancy.
Stephen Kingsmore, M.B., C.h.B., B.A.O., President and CEO, National Center for Genome Resources (NCGR) will present a NCGR study that defined the biochemical profiles of patients with sepsis infections that resulted in various outcomes. A number of biochemical markers were identified that distinguished sepsis from nonsepsis patients as well as biomarkers for sepsis progression.
Michael Milburn, Ph.D., CSO, Metabolon will provide an overview of global biochemical profiling (metabolomics) and its use in the analysis of biological samples for the discovery of markers and pathways associated with drug action and disease.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
AVAILABLE FOR ON-DEMAND VIEWING!
PANELISTS
|
Arun Sreekumar, Ph.D. |
|
Stephen F. Kingsmore, M.B., C.h.B., B.A.O. |
|
Michael Milburn, Ph.D. |
MODERATOR
|
John Sterling |
Produced with support from
